Dyadic International (NASDAQ:DYAI) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Dyadic International (NASDAQ:DYAI) in a report published on Thursday, Marketbeat reports. The firm issued a buy rating and a $3.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Dyadic International’s Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at ($0.04) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.24 EPS.

DYAI has been the subject of several other reports. Craig Hallum assumed coverage on Dyadic International in a report on Monday, September 8th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyadic International in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Stock Performance

DYAI opened at $1.14 on Thursday. The business has a fifty day simple moving average of $1.03 and a 200 day simple moving average of $1.03. The company has a market capitalization of $41.26 million, a PE ratio of -6.00 and a beta of 1.00. Dyadic International has a 1 year low of $0.71 and a 1 year high of $2.20. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.02 and a quick ratio of 2.02.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $0.60 million. Dyadic International had a negative return on equity of 355.39% and a negative net margin of 134.84%. Research analysts expect that Dyadic International will post -0.18 EPS for the current year.

Institutional Investors Weigh In On Dyadic International

Hedge funds have recently added to or reduced their stakes in the business. Callan Capital LLC grew its position in shares of Dyadic International by 86.8% in the 1st quarter. Callan Capital LLC now owns 50,759 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 23,585 shares during the last quarter. Bank of America Corp DE grew its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Chapin Davis Inc. grew its position in shares of Dyadic International by 4.7% in the 2nd quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock valued at $874,000 after buying an additional 40,000 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new stake in shares of Dyadic International in the 2nd quarter valued at about $50,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.